Portal de Periódicos da CAPES

Effect of early two-dose measles vaccination on childhood mortality and modification by maternal measles antibody in Guinea-Bissau, West Africa: A single-centre open-label randomised controlled trial

2022; Elsevier BV; Volume: 49; Linguagem: Inglês

10.1016/j.eclinm.2022.101467

2589-5370

Sebastian Nielsen, Ane Bærent Fisker, Isaquel Silva, Stine Byberg, Sofie Biering‐Sørensen, Carlitos Balé, Amarildo Barbosa, Morten Bjerregaard-Andersen, Nadja Skadkær Hansen, Vu An, Ole Bæk, Stine Møller Rasmussen, Lone Damkjær, Sophus Hvidt, Olga Baltzersen, Amabélia Rodrigues, Cesário Martins, Kristoffer Jarlov Jensen, Hilton Whittle, Gaby Smits, Fiona van der Klis, Peter Aaby, Christine Stabell Benn,

Vaccine Coverage and Hesitancy

Early 2-dose measles vaccine (MV) at 4 and 9 months of age vs. the WHO strategy of MV at 9 months of age reduced all-cause child mortality in a previous trial. We aimed to test two hypotheses: 1) a 2-dose strategy reduces child mortality between 4 and 60 months of age by 30%; 2) receiving early MV at 4 months in the presence versus absence of maternal measles antibodies (MatAb) reduces child mortality by 35%.